MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Name: MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Published: 2021
License: Public Domain

Pfizer · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

multiple-myeloma

multiple myeloma, myeloma, relapsed multiple myeloma, refractory multiple myeloma, pf-06863135, bcma, bispecific, bispecific antibody, bcma-cd3 bispecific, elranatamab, magnetismm-3, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Related documents